BUZZ-RenovoRx rises after $10 mln private stock sale to fund cancer trial, device rollout
Reuters03-18 20:54
BUZZ-RenovoRx rises after $10 mln private stock sale to fund cancer trial, device rollout
** Shares of medical device maker RenovoRx RNXT.O rise 5.6% to $1.02 premarket
** Co says it raised about $10 million in an oversubscribed private stock offering led by institutional investors, with participation from management.
** Adds proceeds from the sale will support the commercial rollout of RenovoCath, an FDA-cleared device that delivers drugs directly to cancer tumors to limit side effects
** Says funds will also back its late-stage study of an experimental combination therapy for pancreatic cancer, which is hard to treat
** Co aims to reach operational breakeven and complete trial enrollment by mid-2026, with results expected in 2027
** Shares up ~15% YTD vs. a ~35% fall in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments